Femcare Ltd Acquires Orion Medical Supplies Ltd in the UK

(PR-inside.com) SALT LAKE CITY, UT / ACCESS Newswire / August 31, 2026 / Femcare Ltd. ("Femcare"), a wholly-owned subsidiary of Utah Medical Products, Inc. (Nasdaq:UTMD), announces that it has purchased the entire ordinary share capital of Orion Medical Supplies Ltd ("ORION") of the United Kingdom. ORION is a niche assembler and distributor, primarily in the UK and Europe, of Harm Reduction medical devices. Harm Reduction refers to programs and practices that aim to minimize negative health, social and legal impacts associated with drug use, drug policies and drug laws. ORION's kits incorporate devices that are designed to reduce the spread of blood ..

USDA Deregulates The Darling 54 American Chestnut

(PR-inside.com) The Historic Decision Moves America's Iconic Tree Closer To Forest-Scale Restoration MCGRAW, NY / ACCESS Newswire / August 31, 2026 / SilvaBio is proud to announce that the U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) have formally deregulated the Darling 54 American chestnut -a landmark achievement in a decades-long effort to restore this species to its 25-state native range. Photo credit John Carnessali Following a thorough, multi-year review process, the agency has determined that the modified American chestnut developed at the SUNY College of Environmental Science and Forestry (ESF) is "unlikely to pose a greater plant pest ..

BODYWELLE Expands Erectile Dysfunction Care With Shockwave Therapy ...

(PR-inside.com) The physician-led practice now offers low-intensity shockwave therapy for erectile dysfunction, following a review of health history, symptoms, and hormone and metabolic panels. MIAMI BEACH, FL / ACCESS Newswire / August 31, 2026 / BODYWELLE , a physician-led longevity and functional medicine practice in Miami Beach, has added low-intensity shockwave therapy to the treatments it offers for erectile dysfunction. The therapy is delivered as part of a men's sexual wellness evaluation rather than as a standalone service, an approach consistent with how the practice treats conditions with vascular and hormonal components. Information about the treatment and the factors that contribute to ..

BODYWELLE Expands Erectile Dysfunction Care With Shockwave Therapy in Miami Beach

The physician-led practice now offers low-intensity shockwave therapy for erectile dysfunction, following a review of health history, symptoms, and hormone and metabolic panels.

Ocumetics Completes Manufacturing of Next Generation Solid State Accommodating Intraocular Lenses for Upcoming Group Two First in Human Clinical Surgeries

CALGARY, ALBERTA - August 31, 2026 ( NEWMEDIAWIRE ) - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce the successful completion of manufacturing of its next generation solid state accommodating intraocular lenses (“Ocumetics Lens”), which will be used in the Company’s upcoming Group Two first-in-human clinical surgeries in Mexico City. The completion of manufacturing represents another significant milestone in Ocumetics’ clinical development program and follows the Company’s encouraging experience with its first group of human patients. Key Highlights - Next-generation Ocumetics Lenses successfully manufactured and ready for the Company’s upcoming Group Two first-in-human clinical surgeries in Mexico City. - Cl

Medical Care Technologies Inc. (OTCID:MDCE) Melanoma Scan Beta Seeks ...

(PR-inside.com) Company Advances Beyond Public Cancer Imaging Datasets With First Real-World User-Submitted Testing Phase MESA, AZ / ACCESS Newswire / August 31, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that its MDCE Melanoma Scan Beta platform is seeking its first set of volunteers for human-submitted dataset testing - a significant step beyond the Company's prior work training and evaluating models solely on established public cancer imaging datasets. Until now, development of MDCE Melanoma Scan Beta has centered on structured internal testing and AI model optimization using gold-standard public dermatology resources, including HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. The move ..

Medical Care Technologies Inc. (OTCID:MDCE) Melanoma Scan Beta Seeks First Volunteer Cohorts for Human-Submitted Image Dataset Testing

Company Advances Beyond Public Cancer Imaging Datasets With First Real-World User-Submitted Testing Phase

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical ...

(PR-inside.com) ~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, and advancing next-generation pain and central nervous system therapeutics designed to reduce abuse and overdose risk, today announced completion of enrollment in the final stage of the PF614-MPAR-102 clinical study. The study evaluated its novel MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology. Unlike traditional abuse-deterrent technologies, PF614-MPAR ..

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides ...

(PR-inside.com) SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides an update on its Measles Drug Treatment Program. While CDC is reviewing the two recent measles-related fatalities in Pennsylvania, the total number of confirmed measles cases in the USA has reached 2,903 as of August 27, 2026, in comparison to 2,289 confirmed cases in the whole year of 2025, indicating continuing expansion of measles1. Cases of ..

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

Wholechain and iFoodDS Integrate to Simplify Compliance with FDA's Food Traceability Rule

Wholechain and iFoodDS have completed a software integration enabling seafood suppliers using Wholechain to seamlessly share critical data across the iFoodDS Trace Exchange™ network to streamline compliance with the FDA's FSMA 204 rule. BLOOMFIELD HILLS, Mich. and SEATTLE, Aug. 31, 2026...